Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia

Weiner-Lastinger, 2020, Antimicrobial-resistant pathogens associated with pediatric healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017, Infect Control Hosp Epidemiol, 41, 19, 10.1017/ice.2019.297 Maragakis, 2008, Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options, Clin Infect Dis, 46, 1254, 10.1086/529198 Leung, 2006, Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome, Chest, 129, 102, 10.1378/chest.129.1.102 Adler, 2014, Acinetobacter baumannii emerging as a multidrug-resistant skin and soft-tissue pathogen: parallels to methicillin-resistant Staphylococcus aureus, JAMA Dermatol, 150, 905, 10.1001/jamadermatol.2013.8855 Peleg, 2008, Acinetobacter baumannii: emergence of a successful pathogen, Clin Microbiol Rev, 21, 538, 10.1128/CMR.00058-07 Liu, 2019, Antimicrobial resistance in South Korea: a report from the Korean global antimicrobial resistance surveillance system (Kor-GLASS) for 2017, J Infect Chemother, 25, 845, 10.1016/j.jiac.2019.06.010 Lemos, 2014, Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis, Clin Microbiol Infect, 20, 416, 10.1111/1469-0691.12363 Du, 2019, Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis, Am J Infect Control, 47, 1140, 10.1016/j.ajic.2019.03.003 Niu, 2018, Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections: cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality, Infect Drug Resist, 11, 2021, 10.2147/IDR.S169432 Kim, 2019, Early intravenous colistin therapy as a favorable prognostic factor for 28-day mortality in patients with CRAB bacteremia: a multicenter propensity score-matching analysis, J Korean Med Sci, 34, e256, 10.3346/jkms.2019.34.e256 Son, 2020, Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia, Open Forum Infect Dis, 7, ofaa378, 10.1093/ofid/ofaa378 Hall, 2006, Updated review of blood culture contamination, Clin Microbiol Rev, 19, 788, 10.1128/CMR.00062-05 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Paterson, 2004, International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections, Ann Intern Med, 140, 26, 10.7326/0003-4819-140-1-200401060-00008 Lambden, 2019, The SOFA score-development, utility and challenges of accurate assessment in clinical trials, Crit Care, 23, 374, 10.1186/s13054-019-2663-7 Katip, 2017, Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients, Infect Drug Resist, 10, 293, 10.2147/IDR.S144314 Kim, 2012, Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy, J Korean Med Sci, 27, 471, 10.3346/jkms.2012.27.5.471 Russo, 2019, Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study, J Infect, 79, 130, 10.1016/j.jinf.2019.05.017 Katip, 2021, Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients, Pharmaceutics, 14 Katip, 2019, Efficacy and safety of high loading dose of colistin in multidrug-resistant Acinetobacter baumannii: a prospective cohort study, J Intensive Care Med, 34, 996, 10.1177/0885066617725694 Katip, 2021, Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis, Pharmaceutics, 13, 10.3390/pharmaceutics13020162 Katip, 2020, A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis, Antibiotics (Basel), 9 Makris, 2018, Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study, Indian J Crit Care Med, 22, 67, 10.4103/ijccm.IJCCM_302_17 Park, 2018, Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia, Int J Antimicrob Agents, 51, 407, 10.1016/j.ijantimicag.2017.10.018 Matuschek, 2018, Antimicrobial susceptibility testing of colistin: evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp, Clin Microbiol Infect, 24, 865, 10.1016/j.cmi.2017.11.020 Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. https://www.eucast.org/eucastguidancedocuments/; 2016 [accessed 13 June 2022]. Falcone, 2022, Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 66, 10.1128/aac.02142-21 Falcone, 2021, Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients, Clin Infect Dis, 72, 2021, 10.1093/cid/ciaa1410 Kim, 2021, Major bloodstream infection-causing bacterial pathogens and their antimicrobial resistance in South Korea, 2017–2019: phase I report from Kor-GLASS, Front Microbiol, 12 Lee, 2013, Comparison of the Vitek 2, MicroScan, and Etest methods with the agar dilution method in assessing colistin susceptibility of bloodstream isolates of Acinetobacter species from a Korean university hospital, J Clin Microbiol, 51, 1924, 10.1128/JCM.00427-13 Kim, 2018, Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: a retrospective multicenter study in Korea, Medicine (Baltimore), 97, e12984, 10.1097/MD.0000000000012984 Zhou, 2018, An emerging clone (ST457) of Acinetobacter baumannii clonal complex 92 with enhanced virulence and increasing endemicity in south China, Clin Infect Dis, 67, S179, 10.1093/cid/ciy691 Jones, 2015, Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence, Clin Infect Dis, 61, 145, 10.1093/cid/civ225